Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             83 results found
no title author magazine year volume issue page(s) type
1 1–26 Accurate Axillary Nodal Staging Can Be Achieved After Neoadjuvant Therapy for Locally Advanced Breast Cancer Breslin, T.M.
 2005
 16 1 p. 57-58
2 p.
 article
2 1–43 Activity and Safety of the Antiestrogen EM-800, the Orally Active Precursor of Acolbifene, in Tamoxifen-Resistant Breast Cancer Elledge, R.M.
 2005
 16 1 p. 82-83
2 p.
 article
3 A Prospective, Randomized, Controlled Clinical Trial of Tissue Adhesive (2-octylcyanoacrylate) Versus Standard Wound Closure in Breast Surgery Leong, W.L.
 2005
 16 1 p. 56-
1 p.
 article
4 1–8 A Prospective Study of Diet and Benign Breast Disease Bevers, T.B.
 2005
 16 1 p. 34-35
2 p.
 article
5 1–42 A Randomized Trial of Exemestane After Two to Three Years of Tamoxifen Therapy in Postmenopausal Women With Primary Breast Cancer Buzdar, A.U.
 2005
 16 1 p. 80-81
2 p.
 article
6 1–4 Association Between Uterine Serous Carcinoma and Breast Cancer Bevers, T.B.
 2005
 16 1 p. 28-
1 p.
 article
7 Benefits and Costs of Interventions to Improve Breast Cancer Outcomes in African American Women Stephens, T.W.
 2005
 16 1 p. 30-
1 p.
 article
8 1–7 Body Size and Breast Cancer Risk: Findings From the European Prospective Investigation Into Cancer and Nutrition (EPIC) Wilder Smith, A.
 2005
 16 1 p. 33-34
2 p.
 article
9 1–25 Breast Abscess in Lactating Women: US-Guided Treatment Bell, J.L.
 2005
 16 1 p. 55-56
2 p.
 article
10 1–38 Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator Brown, P.H.
 2005
 16 1 p. 73-74
2 p.
 article
11 Breast Cancer Prognosis in Relation to Family History of Breast and Ovarian Cancer Bondy, M.L.
 2005
 16 1 p. 36-
1 p.
 article
12 1–40 Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period Giordano, S.H.
 2005
 16 1 p. 76-77
2 p.
 article
13 Breast Necrosis Following Harvest of Internal Mammary Artery Robb, G.L.
 2005
 16 1 p. 92-
1 p.
 article
14 1–16 Can Computer-Aided Detection With Double Reading of Screening Mammograms Help Decrease the False-Negative Rate? Initial Experience Dempsey, P.J.
 2005
 16 1 p. 45-46
2 p.
 article
15 1–20 Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer 2005
 16 1 p. 51-
1 p.
 article
16 Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer Tripathy, Debasish
 2005
 16 1 p. 15-16
2 p.
 article
17 Clinical Outcome and Patients' Satisfaction After Simultaneous Bilateral Breast Reconstruction With Free Transverse Rectus Abdominis Muscle (TRAM) Flap Chang, D.W.
 2005
 16 1 p. 93-
1 p.
 article
18 Contralateral Breast Cancer: Factors Associated With Stage and Size at Presentation Newman, L.A.
 2005
 16 1 p. 29-
1 p.
 article
19 1–51 Cost Minimization Study of Image-Guided Core Biopsy Versus Surgical Excisional Biopsy for Women With Abnormal Mammograms Dempsey, P.J.
 2005
 16 1 p. 94-95
2 p.
 article
20 DNA Fingerprints Provide a Patient-Specific Breast Cancer Marker Brenin, D.R.
 2005
 16 1 p. 29-
1 p.
 article
21 Effect of a Computer-Based Decision Aid on Knowledge, Perceptions, and Intentions About Genetic Testing for Breast Cancer Susceptibility: A Randomized Controlled Trial McCready, D.R.
 2005
 16 1 p. 29-
1 p.
 article
22 Effect of a Decision Aid on Knowledge and Treatment Decision Making for Breast Cancer Surgery: A Randomized Trial Parker, P.A.
 2005
 16 1 p. 56-57
2 p.
 article
23 1–10 Efficacy of MRI and Mammography for Breast-Cancer Screening in Women With a Familial or Genetic Predisposition Orel, S.G.
 2005
 16 1 p. 37-38
2 p.
 article
24 1–45 Efficacy of the Pain Pump Catheter in Immediate Autologous Breast Reconstruction Beahm, E.K.
 2005
 16 1 p. 85-87
3 p.
 article
25 Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Rubio-Viqueira, B.
 2005
 16 1 p. 66-
1 p.
 article
26 Factors Associated With Anastomotic Failure After Microvascular Reconstruction of the Breast Allen, R.J.
 2005
 16 1 p. 92-
1 p.
 article
27 Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342 Holmes, F.A.
 2005
 16 1 p. 79-
1 p.
 article
28 1–50 Family Caregiver Burden: Results of a Longitudinal Study of Breast Cancer Patients and Their Principal Caregivers 2005
 16 1 p. 93-94
2 p.
 article
29 1–13 [18F]FDG in Recurrent Breast Cancer: Diagnostic Performances, Clinical Impact and Relevance of Induced Changes in Management Kim, E.E.
 2005
 16 1 p. 41-42
2 p.
 article
30 1–33 Fusion Cell Vaccination of Patients With Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses Disis, M.L.
 2005
 16 1 p. 65-66
2 p.
 article
31 1–39 Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer Carey, L.A.
 2005
 16 1 p. 74-76
3 p.
 article
32 1–5 Green Tea and the Risk of Breast Cancer: Pooled Analysis of Two Prospective Studies in Japan Russell, N.C.
 2005
 16 1 p. 31-
1 p.
 article
33 1–3 Health-Related Quality of Life Parameters as Prognostic Factors in a Nonmetastatic Breast Cancer Population: An International Multicenter Study Cristofanilli, M
 2005
 16 1 p. 27-
1 p.
 article
34 Immediate Breast Reconstruction Does Not Lead to a Delay in the Delivery of Adjuvant Chemotherapy Robb, G.L.
 2005
 16 1 p. 92-93
2 p.
 article
35 1–2 Impact of BRCA1/BRCA2 Counseling and Testing on Newly Diagnosed Breast Cancer Patients Newman, L.A.
 2005
 16 1 p. 26-
1 p.
 article
36 1–14 Impact of FDG PET on Defining the Extent of Disease and on the Treatment of Patients With Recurrent or Metastatic Breast Cancer Kim, E.E.
 2005
 16 1 p. 42-44
3 p.
 article
37 1–18 Influence of Breast Cancer Histology on the Relationship Between Ultrasound and Pathology Tumor Size Measurements Chagpar, A.B.
 2005
 16 1 p. 48-49
2 p.
 article
38 1–23 Integrated Modeling of Clinical and Gene Expression Information for Personalized Prediction of Disease Outcomes 2005
 16 1 p. 54-
1 p.
 article
39 1–29 Intraoperative Cytologic Examination of Breast Sentinel Lymph Nodes: Test Utility and Patient Impact Klimberg, V.S.
 2005
 16 1 p. 60-
1 p.
 article
40 1–21 Isolated Tumor Cells in Bone Marrow Three Years After Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome Cristofanilli, M.
 2005
 16 1 p. 52-
1 p.
 article
41 1–44 Late Follow-up of a Randomized Trial of Surgery Plus Tamoxifen Versus Tamoxifen Alone in Women Aged Over 70 Years With Operable Breast Cancer Kommareddy, A.
 2005
 16 1 p. 83-84
2 p.
 article
42 Long-term Analysis and Prospective Validation of a Prognostic Model for Patients With High-Risk Primary Breast Cancer Receiving High-Dose Chemotherapy Snyder-Dougherty, L.
 2005
 16 1 p. 78-
1 p.
 article
43 Long-term Cardiac Follow-up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, as Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group Shapiro, C.L.
 2005
 16 1 p. 79-
1 p.
 article
44 1–35 Lymphedema Secondary to Postmastectomy Radiation: Incidence and Risk Factors Taylor, M.E.
 2005
 16 1 p. 69-70
2 p.
 article
45 1–9 Male Breast Cancer: Is the Incidence Increasing? Winchester, D.J.
 2005
 16 1 p. 35-
1 p.
 article
46 1–12 Mammographic Screening and Disease Presentation of Breast Cancer Patients Who Die of Disease Smith, R.A.
 2005
 16 1 p. 40-41
2 p.
 article
47 1–28 Manipulation of the Primary Breast Tumor and the Incidence of Sentinel Node Metastases From Invasive Breast Cancer Page, D.L.
 2005
 16 1 p. 59-
1 p.
 article
48 Maternal Breast Cancer Risk After the Death of a Child Bovbjerg, D.H.
 2005
 16 1 p. 36-
1 p.
 article
49 Melatonin and Breast Cancer: A Prospective Study Grimm, E.A.
 2005
 16 1 p. 30-
1 p.
 article
50 1–37 Multicenter Randomized Phase III Trial of Epirubicin Plus Paclitaxel vs Epirubicin Followed by Paclitaxel in Metastatic Breast Cancer Patients: Focus on Cardiac Safety Seidman, A.D.
 2005
 16 1 p. 71-72
2 p.
 article
51 1–46 Occult Breast Carcinoma in Reduction Mammaplasty Specimens: 14-Year Experience Keleher, A.J.
 2005
 16 1 p. 88-
1 p.
 article
52 1–47 Outcome Study in Liposuction Breast Reduction Chang, D.W.
 2005
 16 1 p. 89-
1 p.
 article
53 Papillary Lesions of the Breast With and Without Atypical Ductal Hyperplasia: Can We Accurately Predict Benign Behavior From Core Needle Biopsy? Gilcrease, M.Z.
 2005
 16 1 p. 50-
1 p.
 article
54 1–17 Patterns of Chromosomal Alterations in Breast Ductal Carcinoma In Situ Sahin, A.A.
 2005
 16 1 p. 46-47
2 p.
 article
55 1–49 Perforator Flap Breast Reconstruction Using Internal Mammary Perforator Branches as a Recipient Site: An Anatomical and Clinical Analysis Langstein, H.N.
 2005
 16 1 p. 91-
1 p.
 article
56 Predictors of Nonsentinel Node Metastasis in Patients With Breast Cancer After Sentinel Node Metastasis Meric-Bernstam, F.
 2005
 16 1 p. 64-
1 p.
 article
57 1–19 Prognostic Relevance of Histological Grade and Its Components in Node-Negative Breast Cancer Patients Gilcrease, M.Z.
 2005
 16 1 p. 49-50
2 p.
 article
58 Proliferative Activity in Primary Breast Carcinomas is a Salient Prognostic Factor El-Naggar, A.K.
 2005
 16 1 p. 50-
1 p.
 article
59 Radiation-Induced Heart Disease in Early Breast Cancer: Problem Solved? Gyenes, Gabor
 2005
 16 1 p. 19-21
3 p.
 article
60 1–41 Randomized Phase II Study of Two Irinotecan Schedules for Patients With Metastatic Breast Cancer Refractory to an Anthracycline, a Taxane, or Both Rothenberg, M.L.
 2005
 16 1 p. 77-78
2 p.
 article
61 1–6 Risk of Breast Cancer Among Users of Aspirin and Other Anti-inflammatory Drugs Vogel, V.G.
 2005
 16 1 p. 32-
1 p.
 article
62 1–15 Screen-Film Mammography Versus Full-Field Digital Mammography With Soft-Copy Reading: Randomized Trial in a Population-Based Screening Program—The Oslo II Study D'Orsi, C.J.
 2005
 16 1 p. 44-45
2 p.
 article
63 1–11 Sensitivity of Noncommercial Computer-Aided Detection System for Mammographic Breast Cancer Detection: Pilot Clinical Trial Dempsey, P.J.
 2005
 16 1 p. 38-40
3 p.
 article
64 1–27 Sentinel Lymph Node Biopsy for Breast Cancer: Improvement in Results Over Time Cody III, H.S.
 2005
 16 1 p. 58-59
2 p.
 article
65 Subareolar Injection of Radioactive Colloid for Sentinel Lymph Node Identification in Breast Cancer Patients Klimberg, V.S.
 2005
 16 1 p. 64-65
2 p.
 article
66 Synergistic Interactions Between Tamoxifen and Trastuzumab (Herceptin) Kommareddy, A.
 2005
 16 1 p. 85-
1 p.
 article
67 1–34 Tamoxifen With or Without Breast Irradiation in Women 50 Years of Age or Older With Early Breast Cancer Buchholz, T.A.
 2005
 16 1 p. 67-69
3 p.
 article
68 1–48 Technical Variations of the Bipedicled TRAM Flap in Unilateral Breast Reconstruction: Effects of Conventional Versus Microsurgical Techniques of Pedicle Transfer on Complications Rates Vasconez, L.O.
 2005
 16 1 p. 90-
1 p.
 article
69 1–30 The Hottest Sentinel Lymph Node Is Not Always the Positive Node Cody III, H.S.
 2005
 16 1 p. 61-
1 p.
 article
70 The Impact of Caregiving on Family Caregivers of Women With Advanced Breast Cancer Grunfeld, Eva
 2005
 16 1 p. 22-24
3 p.
 article
71 The Importance of Validation in Genomic Studies of Breast Cancer Pittman, Jennifer
 2005
 16 1 p. 16-19
4 p.
 article
72 The Internal Mammary Artery and Vein as Recipient Vessels for Microvascular Breast Reconstruction: Are We Burning a Future Bridge? Langstein, H.N.
 2005
 16 1 p. 93-
1 p.
 article
73 The Optimal Number of Sentinel Lymph Nodes for Focused Pathologic Examination Sahin, A.A.
 2005
 16 1 p. 64-
1 p.
 article
74 1–52 The Relationship Among Physicians' Specialty, Perceptions of the Risks and Benefits of Adjuvant Tamoxifen Therapy, and Its Recommendation in Older Patients With Breast Cancer Hughes, K.S.
 2005
 16 1 p. 95-96
2 p.
 article
75 1–32 The Risk of Axillary Relapse After Sentinel Lymph Node Biopsy for Breast Cancer is Comparable With That of Axillary Lymph Node Dissection: A Follow-up Study of 4,008 Procedures Winchester, D.J.
 2005
 16 1 p. 63-64
2 p.
 article
76 1–22 The Role of PTEN and Its Signalling Pathways, Including AKT, in Breast Cancer; An Assessment of Relationships With Other Prognostic Factors and With Outcome Tan, M.
 2005
 16 1 p. 53-54
2 p.
 article
77 1–36 The Use of Alternate, Non-Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-term Results From a Prospective Randomized Trial TL, Smith
 2005
 16 1 p. 70-71
2 p.
 article
78 Three-Year Follow-up on Clinical Symptoms and Health-Related Quality of Life After Reduction Mammaplasty Vasconez, L.O.
 2005
 16 1 p. 92-
1 p.
 article
79 1–24 Use of Preoperative Breast Ultrasonography for Mapping of Breast Cancer Extent Improves Resection Margins During Breast Conservation Surgery Chagpar, A.B.
 2005
 16 1 p. 55-
1 p.
 article
80 Using In Vivo Chemosensitivity as a Guide for Further Systemic Therapy: Refining the Target Population Mamounas, Eleftherios P.
 2005
 16 1 p. 21-22
2 p.
 article
81 1–31 Utility of Axillary Ultrasound Examination to Select Breast Cancer Patients Suited for Optimal Sentinel Node Biopsy Newman, L.A.
 2005
 16 1 p. 61-62
2 p.
 article
82 Variation in Estradiol, Estradiol Precursors, and Estrogen-Related Products in Nipple Aspirate Fluid From Normal Premenopausal Women Kuerer, H.M.
 2005
 16 1 p. 29-
1 p.
 article
83 1–1 What Factors Are Associated With Diagnostic Follow-up After Abnormal Mammograms? Findings From a US National Survey Bevers, T.B.
 2005
 16 1 p. 25-
1 p.
 article
                             83 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands